B Daniele

Summary

Affiliation: Division of Medical Oncology
Country: Italy

Publications

  1. ncbi request reprint Hepatocellular carcinoma: systemic treatments
    Massimo Di Maio
    Medical Oncology, National Cancer Institute, Naples, Italy
    J Clin Gastroenterol 35:S109-14. 2002
  2. pmc Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial
    B Daniele
    Divisione di Oncologia Medica B, Istituto Nazionale Tumori, Napoli, Italy
    Gut 48:28-33. 2001
  3. ncbi request reprint Effect of chemotherapy with 5-fluorouracil on intestinal permeability and absorption in patients with advanced colorectal cancer
    B Daniele
    Division of Medical Oncology, National Cancer Institue, Napoli, Italy
    J Clin Gastroenterol 32:228-30. 2001
  4. ncbi request reprint Ischemic colitis associated with paclitaxel
    B Daniele
    Department of Medical Oncology, National Cancer Institute and G Pascale Foundation, Naples, Italy
    J Clin Gastroenterol 33:159-60. 2001
  5. ncbi request reprint [Multivisceral resection of advanced gastric cancer]
    R Palaia
    Unità Operativa Complessa di Oncologica Chirurgia C, Istituto Nazionale Tumori, Napoli
    Tumori 89:121-4. 2003
  6. ncbi request reprint Prognostic value of serum biological markers in patients with hepatocellular carcinoma
    R Parasole
    Division of Clinical Immunology, National Cancer Institute, Via M. Semmola, 80131 Naples, Italy
    Clin Cancer Res 7:3504-9. 2001
  7. ncbi request reprint Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicentre randomised controlled trial
    F Perrone
    CLIP secretariat, Ufficio Sperimentazioni Cliniche Controllate, Istituto Nazionale Tumori, Via Mariano Semmola, Napoli, 80131, Italy
    Curr Pharm Des 8:1013-9. 2002
  8. ncbi request reprint Plasma postheparin diamine oxidase in patients with small intestinal lymphoma
    L D'Agostino
    Cattedra di Gastroenterologia, 2a Facolta di Medicina, Universita Federico II, Napoli, Italy
    Cancer 67:511-5. 1991
  9. ncbi request reprint Originality, benefits and difficulties of clinical research performed by cooperative groups: the experience of an Italian Lung Cancer Study Group
    C Gridelli
    Divisione di Oncologia Medica B, Istituto Nazionale Tumori, Via M Semmola 3, 80131, Naples, Italy
    Crit Rev Oncol Hematol 36:3-8. 2000
  10. pmc Is human hepatocellular carcinoma a hormone-responsive tumor?
    Massimo Di Maio
    Medical Oncology, N Giannettasio Hospital, Rossano 87068, Italy
    World J Gastroenterol 14:1682-9. 2008

Collaborators

Detail Information

Publications25

  1. ncbi request reprint Hepatocellular carcinoma: systemic treatments
    Massimo Di Maio
    Medical Oncology, National Cancer Institute, Naples, Italy
    J Clin Gastroenterol 35:S109-14. 2002
    ..In the future, innovative and promising therapeutic strategies will be tested in HCC, including new biologic target-based drugs, cyclooxygenase inhibitors, and gene therapy...
  2. pmc Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial
    B Daniele
    Divisione di Oncologia Medica B, Istituto Nazionale Tumori, Napoli, Italy
    Gut 48:28-33. 2001
    ..Animal and human studies suggest that glutamine stimulates intestinal mucosal growth...
  3. ncbi request reprint Effect of chemotherapy with 5-fluorouracil on intestinal permeability and absorption in patients with advanced colorectal cancer
    B Daniele
    Division of Medical Oncology, National Cancer Institue, Napoli, Italy
    J Clin Gastroenterol 32:228-30. 2001
    ..Cellobiose-mannitol ratio and D-xylose absorption tests can be used for the assessment of toxic effect of 5-FU on mature intestinal epithelium and also for evaluating the role of cytoprotective agents...
  4. ncbi request reprint Ischemic colitis associated with paclitaxel
    B Daniele
    Department of Medical Oncology, National Cancer Institute and G Pascale Foundation, Naples, Italy
    J Clin Gastroenterol 33:159-60. 2001
    ..Once C. difficile infection has been excluded, a diagnosis of ischemic colitis should be considered, especially in patients with cancer who have normal white blood cell counts...
  5. ncbi request reprint [Multivisceral resection of advanced gastric cancer]
    R Palaia
    Unità Operativa Complessa di Oncologica Chirurgia C, Istituto Nazionale Tumori, Napoli
    Tumori 89:121-4. 2003
  6. ncbi request reprint Prognostic value of serum biological markers in patients with hepatocellular carcinoma
    R Parasole
    Division of Clinical Immunology, National Cancer Institute, Via M. Semmola, 80131 Naples, Italy
    Clin Cancer Res 7:3504-9. 2001
    ..51 (95% confidence interval, 0.76-3.01). CONCLUSIONS: Serum levels of sICAM-1, sIL-2R, IL-6, and anti-p53 are not useful as prognostic factors for HCC in clinical practice. They do not improve the predictive ability of the CLIP score...
  7. ncbi request reprint Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicentre randomised controlled trial
    F Perrone
    CLIP secretariat, Ufficio Sperimentazioni Cliniche Controllate, Istituto Nazionale Tumori, Via Mariano Semmola, Napoli, 80131, Italy
    Curr Pharm Des 8:1013-9. 2002
    ..control. Here we report an updated analysis of the study results 4.5 years after the closure of enrollment...
  8. ncbi request reprint Plasma postheparin diamine oxidase in patients with small intestinal lymphoma
    L D'Agostino
    Cattedra di Gastroenterologia, 2a Facolta di Medicina, Universita Federico II, Napoli, Italy
    Cancer 67:511-5. 1991
    ..Our data indicate that in patients with small bowel lymphoma PHD test is a sensitive marker of small bowel mucosa damage and suggest that it could be useful in monitoring the recovery of mucosal lesions induced by chemotherapy...
  9. ncbi request reprint Originality, benefits and difficulties of clinical research performed by cooperative groups: the experience of an Italian Lung Cancer Study Group
    C Gridelli
    Divisione di Oncologia Medica B, Istituto Nazionale Tumori, Via M Semmola 3, 80131, Naples, Italy
    Crit Rev Oncol Hematol 36:3-8. 2000
    ..Our group is giving significant contributions to the field of lung cancer. Today, large controlled clinical trials are ongoing...
  10. pmc Is human hepatocellular carcinoma a hormone-responsive tumor?
    Massimo Di Maio
    Medical Oncology, N Giannettasio Hospital, Rossano 87068, Italy
    World J Gastroenterol 14:1682-9. 2008
    ..Negative results have been obtained also with anti-androgen therapy. In conclusion, there is no robust evidence to consider HCC a hormone-responsive tumor. Hormonal treatments should not be part of the current management of HCC...
  11. ncbi request reprint Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study
    Cesare Gridelli
    Medical Oncology, S Giuseppe Moscati Hospital, Avellino, Italy
    Lancet Oncol 8:500-12. 2007
    ..We aimed to assess whether the addition of rofecoxib or PCI gemcitabine could improve overall survival compared with first-line treatment with cisplatin plus gemcitabine given by standard infusion...
  12. ncbi request reprint Characteristics at presentation and outcome of hepatocellular carcinoma (HCC) in the elderly. A study of the Cancer of the Liver Italian Program (CLIP)
    Sandro Pignata
    Oncologia Medica B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Napoli, Italy
    Crit Rev Oncol Hematol 59:243-9. 2006
    ..To describe the characteristics at presentation and the outcome of elderly patients (> or =70 years old) with HCC, a retrospective analysis using a CLIP database was performed...
  13. pmc Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma
    Ciro Gallo
    Department of Medicine and Public Health, Second University, Naples, Italy
    BMC Cancer 6:196. 2006
    ..However, a recent report suggested that the drug might prolong survival among patients with well preserved liver function. The aim of this paper is to validate this hypothesis...
  14. ncbi request reprint Stop Flow in abdominal and pelvic cancer relapses
    Rosario Vincenzo Iaffaioli
    Med Onc B INT Naples, Cagliari University, Italy
    Front Biosci 11:1284-8. 2006
    ..Stop-Flow is a safe and feasible technique very useful as a palliation treatment...
  15. ncbi request reprint Second-line intra-arterial chemotherapy in advanced pancreatic adenocarcinoma
    Emiddio Barletta
    Department of Oncology, G Rummo Hospital, 82100, Benevento, Italy
    Front Biosci 11:782-7. 2006
    ..0446) significantly improved after therapy. No patient discontinued treatment because of toxicity (NCI-CTC criteria). The current study shows that intraarterial chemotherapy is a good therapeutic option in second-line treatment of LAMPC...
  16. ncbi request reprint [Screening of hepatocellular carcinoma: role of the alpha-fetoprotein (AFP) and ultrasonography]
    Emiddio Barletta
    Recenti Prog Med 96:295-9; quiz 328. 2005
    ..Pathology assessment of liver explants in living donor transplantation programs will provide more precise and reliable information regarding the value of AFP and ultrasonography as HCC screening tools...
  17. ncbi request reprint Staging for liver cancer
    Bruno Daniele
    Medical Oncology Unit, G Rummo Hospital, Benevento, Italy
    Clin Liver Dis 9:213-23, vi. 2005
    ..The peculiarity of hepatocellular carcinoma patients are addressed, and each individual prognostic systems for hepatocellular carcinoma is presented and discussed...
  18. ncbi request reprint Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma
    Bruno Daniele
    Medical Oncology Unit, G Rummo Hospital, Via dell Angelo 1, 82100 Benevento, Italy
    Gastroenterology 127:S108-12. 2004
    ..US seems more efficient as a screening tool. Pathology assessment of liver explants in living-donor transplantation programs will provide more precise and reliable information regarding the value of AFP and US as HCC screening tools...
  19. pmc Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients
    Steven A Curley
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Ann Surg 239:450-8. 2004
    ..We performed this prospective analysis to determine early (within 30 days) and late (more than 30 days after) complication rates associated with hepatic tumor RFA...
  20. ncbi request reprint Transcatheter arterial procedures in the treatment of patients with hepatocellular carcinoma: a review of literature
    Ermelinda De Maio
    Medical Oncology B, National Cancer Institute of Naples, Via M Semmola, 80131, Naples, Italy
    Crit Rev Oncol Hematol 46:285-95. 2003
    ....
  21. ncbi request reprint Feasibility of adjuvant hepatic arterial infusion of chemotherapy after radiofrequency ablation with or without resection in patients with hepatic metastases from colorectal cancer
    Courtney L Scaife
    Departments of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Surg Oncol 10:348-54. 2003
    ..We conducted a study to determine the feasibility of using HAI after RFA for colorectal cancer (CRC) liver metastases...
  22. ncbi request reprint First-line chemotherapy with fluorouracil and folinic acid for advanced colorectal cancer in elderly patients: a phase II study
    Bruno Daniele
    Medical Oncology, Clinical Trial Office, National Cancer Institute of Naples, Italy
    J Clin Gastroenterol 36:228-33. 2003
    ....
  23. ncbi request reprint Hepatic resection and percutaneous ethanol injection as treatments of small hepatocellular carcinoma: a Cancer of the Liver Italian Program (CLIP 08) retrospective case-control study
    Bruno Daniele
    Oncologia Medica B, Oncologia Chirurgica CM, Istituto Nazionale Tumori, Napoli, Italy
    J Clin Gastroenterol 36:63-7. 2003
    ..Patients with small hepatocellular carcinoma (HCC) are usually treated with hepatic resection or percutaneous ethanol injection (PEI)...
  24. ncbi request reprint Clinical features, etiology, and survival of hepatocellular carcinoma among different countries
    Masao Omata
    Department of Gastroenterology, University of Tokyo Graduate School of Medicine, Japan
    J Gastroenterol Hepatol 17:S40-9. 2002
  25. doi request reprint Re: Design and endpoints of clinical trials in hepatocellular carcinoma
    Massimo Di Maio
    J Natl Cancer Inst 100:1557; author reply 1557-8. 2008